Reintroduction of ruxolitinib following toxicity from momelotinib in a 74-year-old female with secondary myelofibrosis: a case study
Clinical Scorecard: Reintroduction of ruxolitinib following toxicity from momelotinib in a 74-year-old female with secondary myelofibrosis: a case study
At a Glance
Category Detail
Condition Secondary Myelofibrosis Key Mechanisms JAK1/2 inhibition, ACVR1 inhibition, hepcidin suppression Target Population Patients with secondary myelofibrosis and treatment-related toxicities Care Setting Hematology consultation and management
Key Highlights
74-year-old female with secondary myelofibrosis switched from ruxolitinib to momelotinib due to anemia. Developed peripheral neuropathy and arthralgias on momelotinib. Successfully reintroduced low-dose ruxolitinib after momelotinib toxicity. Ruxolitinib reintroduction improved anemia control and resolved neuropathy. Case highlights the potential for JAK inhibitor rechallenge in managing adverse effects. Guideline-Based Recommendations
Diagnosis
Diagnosis of myelofibrosis based on clinical and laboratory features. Management
Initial treatment with ruxolitinib for symptomatic management. Consideration of momelotinib for anemia management. Monitoring & Follow-up
Regular assessment of hemoglobin levels and symptom control. Monitoring for adverse effects, particularly neuropathy. Risks
Risk of treatment-emergent adverse events such as peripheral neuropathy and thrombocytopenia. Patient & Prescribing Data
Older adults with secondary myelofibrosis and prior treatment-related toxicities.
Sequential use of JAK inhibitors may be beneficial in managing symptoms and adverse effects.
Clinical Best Practices
Individualized treatment plans based on patient response and tolerance. Close monitoring of hematologic parameters and symptomatology during treatment. Related Resources & Content
